Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2019, Article ID 6537815, 2 pages
Case Report

Sodium Oxybate: A Cause of Extreme Involuntary Weight Loss in a Young Lady

Department of Medicine, Duke University Medical Center, 2301 Erwin Rd, 27703 Durham, NC, USA

Correspondence should be addressed to Michael G. Noujaim; ude.ekud@9ngm

Received 5 June 2019; Revised 1 July 2019; Accepted 14 July 2019; Published 24 July 2019

Academic Editor: Bruno Megarbane

Copyright © 2019 Michael G. Noujaim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UpToDate (Internet), Sodium Oxybate (Gamma Hydroxybutyrate): Drug Information, UpToDate, Waltham, MA, USA, 2019.
  2. A. M. Husain, R. K. Ristanovic, and R. K. Bogan, “Weight loss in narcolepsy patients treated with sodium oxybate,” Sleep Medicine, vol. 10, no. 6, pp. 661–663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. S. Schinkelshoek, I. M. Smolders, C. E. Donjacour et al., “Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1,” Journal of Sleep Research, vol. 28, no. 3, Article ID e12684, 2019. View at Publisher · View at Google Scholar
  4. I. R. Edwards and J. K. Aronson, “Adverse drug reactions: definitions, diagnosis, and management,” The Lancet, vol. 356, no. 9237, pp. 1255–1259, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. C. A. Naranjo, U. Busto, E. M. Sellers et al., “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981. View at Publisher · View at Google Scholar · View at Scopus